TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
Aditya BardiaLajos PusztaiKathy AlbainEva Maria CiruelosSeock-Ah ImDawn HershmanKevin KalinskyClaudine IsaacsDelphine LoiratLaura TestaEriko TokunagaJiong WuHannah DryWilliam BarlowRobert KozarskiMicah MaxwellNadia HarbeckPriyanka SharmaPublished in: Therapeutic advances in medical oncology (2024)
ClinicalTrials.gov identifier: NCT05629585 (registration date: 29 November 2022).